Zacks Bull and Bear of the Day Highlights: Brookfield Infrastructure Partners, Bunge, Teva Pharmaceutical Industries, Shire and Bayer

Feb 22, 2013, 09:30 ET from Zacks Investment Research, Inc.

CHICAGO, Feb. 22, 2013 /PRNewswire/ -- Zacks Equity Research highlights Brookfield Infrastructure Partners (NYSE: BIP) as the Bull of the Day and Bunge Limited (NYSE: BG) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Shire (Nasdaq: SHPG) and Bayer (OTC:BAYRY).


Full analysis of all these stocks is available at

Here is a synopsis of all five stocks:

Bull of the Day:

Founded in 2007, Brookfield Infrastructure Partners (NYSE: BIP) is a global owner and operator of high quality infrastructure assets in utilities, transportation, energy and timber businesses. Based in Bermuda, the partnership owns holding corporations in the U.S., Canada and other jurisdiction.

The high quality, long life assets allow the partnership to generate solid and consistent cash flow. Brookfield Infrastructure Partners L.P. is a subsidiary of Brookfield Asset Management Inc. The company has a market capitalization of ~$8 billion and is traded on NYSE and TSX exchanges.

The board of directors of Brookfield Infrastructure Partners approved to increase the quarterly cash distribution rate to $0.43 per unit, a 15% increase from $0.375 distributed in the previous quarter.

The company has an excellent track record of distribution growth—compound annual growth of over 10% over past five years and has a very attractive distribution yield of ~4.5% currently.

Further, the distributions are backed by stable cash flows as 85% of the cash flows are generated from regulated business or long-term contacts.

 Bear of the Day:

Bunge Limited (NYSE: BG), based in White Plains, NY, is a leading agribusiness and food company with integrated operations all over the world—in about 40 countries. It is a global leader in oilseed processing, and grain & oilseed marketing. The company has four business segments 1) Agribusiness, 2) Sugar & Bioenergy 3) Food & Ingredients and 4) Fertilizers.

The company came out with its IPO in 2001 and has expanded though many significant acquisitions since then.

BG released its results for the fourth quarter of 2012 on February 7, 2013. The quarter resulted in a loss of $1.99 per diluted share from continuing operations, before adjustments.

Disappointing results were mainly due to weak performance by the Agribusiness segment and a loss in the Sugar & Bioenergy segment. Rising corn costs, foreign exchange losses and weak global economic conditions hurt the results.

 Latest Posts on the Zacks Analyst Blog:

FDA Approves Teva's Generic Adderal

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) recently announced that it has gained US Food and Drug Administration (FDA) approval for its generic version of Shire's (Nasdaq: SHPG) Adderall XR capsules (5mg, 10mg, 15mg, 20mg, 25mg and 30 mg).

According to IMS, Adderall XR, which is approved for the treatment of attention deficit hyperactivity disorder, delivered annual sales (both branded and generic) of about $2 billion in the US as of Dec 31, 2012.

Teva already sells a generic version of Adderall XR under a 2006 license and distribution agreement with Shire. Per the terms of the agreement, Shire has to supply product to Teva through Apr 1, 2014.

With the FDA granting final approval, Teva can now remain in the Adderall XR market even after the expiry of its supply agreement with Shire.

Teva currently carries a Zacks Rank #3 (Hold). The company, which is going through a transition period, provided disappointing guidance for 2013. However, with the company not including the impact of its cost-savings plan in its guidance, we believe Teva is leaving some room for delivering above expectations. Share buybacks also leave some room for upside.

We expect investor focus to remain on the execution of the company's new strategy. Earlier this year, Teva sold off its animal health business in the US to Bayer (OTC:BAYRY). This will allow the company to focus on developing, manufacturing and marketing branded and generic drugs globally -- Teva's primary areas of strength.

Get the full analysis of all these stocks by going to

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.